Atovaquon/Proguanilhydrochlorid Glenmark

Atovaquone/Proguanil Hydrochloride Glenmark is a combination medication used to prevent and treat malaria. This oral treatment is manufactured by Glenmark Arzneimittel Gmbh and is suitable for oral use.

Atovaquone/Proguanil Hydrochloride Glenmark is primarily used for the prevention and treatment of malaria, a mosquito-borne disease caused by parasites. It works by interfering with the growth of parasites in the red blood cells. This medication is often prescribed for travelers to areas where malaria is common, as well as for those who have been exposed to the disease.

Common effects of Atovaquone/Proguanil Hydrochloride Glenmark may include nausea, vomiting, diarrhea, and stomach pain. Some users may also experience headache, dizziness, or cough. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare professional.

Atovaquone/Proguanil Hydrochloride Glenmark should be used with caution in individuals with severe kidney or liver problems. It is important to follow the prescribed dosage and complete the full course of treatment, even if symptoms improve. This medication should be stored at room temperature and kept out of reach of children.

Atovaquone/Proguanil Hydrochloride Glenmark may interact with certain medications, including antacids, metoclopramide, and drugs that affect the liver or kidneys. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol should be avoided while taking this medication.